Document ID: chunk:federal_register_of_legislation:F2009B00223:body:0:p4
Version: federal_register_of_legislation:F2009B00223
Segment Type: other
Provision Reference: 
Character Range: 8481–11714

out the project; and

           (c) disclose to the Board any government funding that the applicant has received or will receive in relation to the project.

       (2) The Board must not approve an application for financial assistance for part of the eligible expenditure on a project unless the Board is satisfied that the applicant is able to fund the rest of the eligible expenditure on the project (matching funding).

       (3) For the purposes of subclause 10(2), the Board must not take into account:

           (a) funding obtained by the applicant under a program administered by the Board or the Department of Industry Science and Resources except the Innovation Investment Fund and Pooled Development Funds;

           (b) funding of a kind that a guideline or determination states is not to be regarded as matching funding; or

           (c) non-financial (in kind) assistance obtained by the applicant.

Project requirements

    11. (1) A project to which an application relates:

           (a) must be for the commercialisation of biotechnology;

           (b) must be for the proof of concept stage of development;

           (c) may involve strategies for intellectual property protection; and

           (d) may involve related business planning and market development studies.

PART 5 — MERIT CRITERIA

Assessment of applications

    12. If the Board accepts an application made in relation to a funding round, it must assess the application by comparing the merit of the application with the merit of other applications accepted by the Board made in relation to that funding round.

Merit criteria

    13. (1) The merit of applications must be assessed under the following criteria:

           (a) the extent to which the applicant's company structure and arrangements will facilitate commercialisation, including:

              (i) the extent to which the applicant has a commercial focus demonstrated, for example, by:

                  (A) the commercial skills and experience of the applicant's board and management;

                  (B) an appropriate business plan;

                  (C) strategic partnerships between the applicant and commercially focussed organisations; or

                  (D) other links that the applicant has to commercial skills and experience;

              (ii) the extent to which the applicant is owned by persons in the private sector;

              (iii) the extent to which the applicant has or will have its own funds at risk in relation to the project; and

              (iv) the capacity of the applicant to commercialise the biotechnology to which the application relates demonstrated, for example, by:

                  (A) commitment by the applicant and its management to the project; or

                  (B) the management and planning skills of the applicant's key personnel relating to research, commercial and financial areas or other access the applicant has to those skills;

           (b) the extent to which the project will contribute to the commercialisation of leading edge biotechnology including:

              (i) the commercialisation potential of the biotechnology to which the application relates